Meridian Closes Acquisition of BreathTek® Business

Rhea-AI Summary

CINCINNATI, Aug. 2, 2021 - Meridian Bioscience announced the acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, effective July 31, 2021. This strategic move aims to enhance Meridian's diagnostic testing solutions and strengthen its market position. Financial impacts related to the acquisition will be discussed in the upcoming quarterly earnings call on August 6, 2021. Meridian is a global leader in diagnostic solutions, trading under the NASDAQ symbol VIVO.

Positive

• Acquisition of North American BreathTek® business strengthens diagnostic solutions portfolio.
• Expected financial benefits to be discussed in the upcoming earnings call.

Negative

• Financial impact details on the acquisition remain unclear until earnings call.
• -

CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek^® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021.

Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021.

About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com.

Contact:
Charlie Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com

FAQ

What is the significance of Meridian's acquisition of BreathTek®?

The acquisition enhances Meridian's diagnostic testing capabilities and market presence.

When was the BreathTek® acquisition effective?

The acquisition was effective on July 31, 2021.

What will be discussed in the upcoming earnings call on August 6, 2021?

The earnings call will cover the financial impacts of the BreathTek® acquisition.

What does Meridian Bioscience specialize in?

Meridian specializes in diagnostic testing solutions and life science raw materials.